Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Mar;45(3):413–420. doi: 10.1038/bjc.1982.69

Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.

R Shepherd, K R Harrap
PMCID: PMC2010934  PMID: 7073935

Abstract

The steroids prednisolone and progesterone significantly altered the therapeutic indices of the alkylating agents, nitrogen mustard, melphalan, cyclophosphamide, phenyl acetic mustard and chlorambucil. For nitrogen mustard, chlorambucil and phenyl acetic mustard, prednisolone reduced host toxicity in the rat and enhanced the antitumour effectiveness against alkylating-agent-resistant strains of the Yoshida sarcoma and Walker carcinosarcoma. Progesterone also increased the therapeutic index of chlorambucil in the rat by decreasing its systemic toxicity. Two other alkylating agents, melphalan and cyclophosphamide, exhibited lower therapeutic indices in combination with prednisolone against alkylating-agent-sensitive tumours. This was due to the greater host toxicity of the combination than of the alkylating agent alone. In alkylating-agent-resistant tumours, however, a significant increase in growth delay was achieved if prednisolone was combined with the alkylating agent.

Full text

PDF
413

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P., Gottlieb J. A., Livingston R., Frei E., 3rd New agents and combinations in the treatment of bronchogenic carcinoma. Cancer Chemother Rep 3. 1973 Mar;4(2):227–229. [PubMed] [Google Scholar]
  2. Braganca B. M., Hospattankar A. V. Potentiating action of cobra venom cytotoxin on the antitumour effects of an alkylating agent (melphalan). Eur J Cancer. 1978 Jun;14(6):707–712. doi: 10.1016/0014-2964(78)90307-9. [DOI] [PubMed] [Google Scholar]
  3. Braunschweiger P. G., Stragand J. J., Schiffer L. M. Effect of methylprednisolone on cell proliferation in C3H/HeJ spontaneous mammary tumors. Cancer Res. 1978 Dec;38(12):4510–4514. [PubMed] [Google Scholar]
  4. Brox L. W., Gowans B., Belch A. L-phenylalanine mustard (melphalan) uptake and cross-linking in the RPMI 6410 human lymphoblastoid cell line. Cancer Res. 1980 Apr;40(4):1169–1172. [PubMed] [Google Scholar]
  5. Burroughs S. F., Cidlowski J. A. Glucocorticoid and mitogen sensitivity of rat splenic and thymic lymphocytes in vitro after in vivo cyclophosphamide treatment. Cancer Res. 1978 Dec;38(12):4562–4568. [PubMed] [Google Scholar]
  6. Cohen J. J. Thymus-derived lymphocytes sequestered in the bone marrow of hydrocortisone-treated mice. J Immunol. 1972 Mar;108(3):841–844. [PubMed] [Google Scholar]
  7. Connors T. A., Jones M., Ross W. C., Braddock P. D., Khokhar A. R., Tobe M. L. New platinum complexes with anti-tumour activity. Chem Biol Interact. 1972 Nov;5(6):415–424. doi: 10.1016/0009-2797(72)90078-6. [DOI] [PubMed] [Google Scholar]
  8. El Dareer S. M., Struck R. F., White V. M., Mellett L. B., Hill D. L. Distribution and metabolism of prednisone in mice, dogs, and monkeys. Cancer Treat Rep. 1977 Oct;61(7):1279–1289. [PubMed] [Google Scholar]
  9. Enck R. E., Bennett J. M. Inadvertent chlorambucil overdose in adult. N Y State J Med. 1977 Aug;77(9):1480–1485. [PubMed] [Google Scholar]
  10. Fauci A. S., Dale D. C. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest. 1974 Jan;53(1):240–246. doi: 10.1172/JCI107544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fauci A. S. Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and b lymphocytes to the bone marrow. Immunology. 1975 Apr;28(4):669–680. [PMC free article] [PubMed] [Google Scholar]
  12. Gerber N. L., Powell D., Steinberg A. D. Therapeutic studies in NZB/NZW F1 mice. V. Comparison of cyclophosphamide and chlorambucil. Arthritis Rheum. 1977 Jul-Aug;20(6):1263–1268. doi: 10.1002/art.1780200615. [DOI] [PubMed] [Google Scholar]
  13. Han T., Ezdinli E. Z., Shimaoka K., Desai D. V. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer. 1973 Mar;31(3):502–508. doi: 10.1002/1097-0142(197303)31:3<502::aid-cncr2820310303>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  14. Harrap K. R., Furness M. E. The cytotoxicity of chlorambucil and its associated effects on NAD metabolism. Eur J Cancer. 1973 May;9(5):343–351. doi: 10.1016/0014-2964(73)90049-2. [DOI] [PubMed] [Google Scholar]
  15. Harrap K. R., Hill B. T. The selectivity of action of alkylating agents and drug resistance. II. A comparison of the effects of alkylating drugs on growth inhibition and cell size in sensitive and resistant strains of the Yoshida ascites sarcoma. Br J Cancer. 1969 Mar;23(1):227–234. doi: 10.1038/bjc.1969.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Harrap K. R., Riches P. G., Gilby E. D., Sellwood S. M., Wilkinson R., Konyves I. Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucil. Eur J Cancer. 1977 Aug;13(8):873–881. doi: 10.1016/0014-2964(77)90143-8. [DOI] [PubMed] [Google Scholar]
  17. Hedley D. W., McElwain T. J., Millar J. L., Gordon M. Y. Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan. Lancet. 1978 Nov 4;2(8097):966–968. doi: 10.1016/s0140-6736(78)92529-1. [DOI] [PubMed] [Google Scholar]
  18. Hill B. T., Harrap K. R. Modification of the alkylating ability of cyclophosphamide by fresh plasma. Chem Biol Interact. 1972 Jul;5(2):117–125. doi: 10.1016/0009-2797(72)90038-5. [DOI] [PubMed] [Google Scholar]
  19. Hill B. T., Jarman M., Harrap K. R. Selectivity of action of alkylating agents and drug resistance. 4. Synthesis of tritium-labeled chlorambucil and a study of its cellular uptake by drug-sensitive and drug-resistant strains of the Yoshida ascites sarcoma in vitro. J Med Chem. 1971 Jul;14(17):614–68-. doi: 10.1021/jm00289a012. [DOI] [PubMed] [Google Scholar]
  20. Joyce R. A., Chervenick P. A. Corticosteroid effect on granulopoiesis in mice after cyclophosphamide. J Clin Invest. 1977 Aug;60(2):277–283. doi: 10.1172/JCI108775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Land V. J., Sutow W. W., Dyment P. G., Falletta J. M., Morgan S. K., Bryan J. Remission induction with L-asparaginase, vincristine, and prednisone in children with acute nonlymphoblastic leukemia. Med Pediatr Oncol. 1976;2(2):191–198. doi: 10.1002/mpo.2950020209. [DOI] [PubMed] [Google Scholar]
  22. McElwain T. J., Toy J., Smith E., Peckham M. J., Austin D. E. A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease. Br J Cancer. 1977 Aug;36(2):276–280. doi: 10.1038/bjc.1977.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McLean A., Newell D., Baker G. The metabolism of chlorambucil. Biochem Pharmacol. 1976 Oct 15;25(20):2331–2335. doi: 10.1016/0006-2952(76)90019-8. [DOI] [PubMed] [Google Scholar]
  24. Newell D. R., Hart L. I., Harrap K. R. Estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography. J Chromatogr. 1979 Sep 11;164(1):114–119. doi: 10.1016/s0378-4347(00)81580-7. [DOI] [PubMed] [Google Scholar]
  25. Newell D. R., Shepherd C. R., Harrap K. R. The pharmacokinetics of prednimustine and chlorambucil in the rat. Cancer Chemother Pharmacol. 1981;6(1):85–91. doi: 10.1007/BF00253015. [DOI] [PubMed] [Google Scholar]
  26. Redwood W. R., Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res. 1980 Apr;40(4):1144–1149. [PubMed] [Google Scholar]
  27. Rosenoer V. M., Mitchley B. C., Roe F. J., Connors T. A. Walker carcinosarcoma 256 in study of anticancer agents. I. Method for simultaneous assessment of therapeutic value and toxicity. Cancer Res. 1966 Aug;26(8 Pt 2):937–941. [PubMed] [Google Scholar]
  28. Rosner F., Hirshaut Y., Grünwald H. W., Dietrich M. In vitro combination chemotherapy demonstrating potentiation of vincristine cytotoxicity by prednisolone. Cancer Res. 1975 Mar;35(3):700–705. [PubMed] [Google Scholar]
  29. Ross W. E., Ewig R. A., Kohn K. W. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res. 1978 Jun;38(6):1502–1506. [PubMed] [Google Scholar]
  30. Scavino H. F., George J. N., Sears D. A. Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone. Cancer. 1976 Aug;38(2):672–677. doi: 10.1002/1097-0142(197608)38:2<672::aid-cncr2820380208>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  31. Simpson H. W., Stoney P. J. A circadian variation of melphalan (L-phenylalanine nitrogen mustard) toxicity to murine bone marrow: relevance to cancer treatment protocols. Br J Haematol. 1977 Mar;35(3):459–464. doi: 10.1111/j.1365-2141.1977.tb00607.x. [DOI] [PubMed] [Google Scholar]
  32. Tisdale M. J., Phillips B. J. Alterations in adenosine 3', 5'-monophosphate-binding protein in Walker carcinoma cells sensitive or resistant to alkylating agents. Biochem Pharmacol. 1976 Aug 15;25(16):1831–1836. doi: 10.1016/0006-2952(76)90186-6. [DOI] [PubMed] [Google Scholar]
  33. Tucker W. G., Talley R. W., Brownlee R. W., Burrows J. H., Stott P. B., Moorhead E. L., 2nd, San Diego E. L. Preliminary trials with combination therapy of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-19893). Cancer Chemother Rep. 1968 Sep;52(5):593–596. [PubMed] [Google Scholar]
  34. Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation. Br Med J. 1975 Aug 16;3(5980):413–414. doi: 10.1136/bmj.3.5980.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Whitecar J. P., Jr, Bodey G. P., Freireich E. J., McCredie K. B., Hart J. S. Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep. 1972 Aug;56(4):543–550. [PubMed] [Google Scholar]
  36. Wilkinson R., Birbeck M. S., Harrap K. R. Enhancement of the nuclear reactivity of alkylating agents by prednisolone. Cancer Res. 1979 Oct;39(10):4256–4262. [PubMed] [Google Scholar]
  37. Ziegler J. L., Bluming A. Z., Fass L., Morrow R. H., Jr Relapse patterns in Burkitt's lymphoma. Cancer Res. 1972 Jun;32(6):1267–1272. [PubMed] [Google Scholar]
  38. van Putten L. M., Lelieveld P. Factors determining cell killing by chemotherapeutic agents in vivo. II. Melphalan, chlorambucil and nitrogen mustard. Eur J Cancer. 1971 Feb;7(1):11–16. doi: 10.1016/0014-2964(71)90089-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES